NCT03439735View on ClinicalTrials.gov

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 20, 2018

Primary Completion Date

August 1, 2026

Study Completion Date

November 1, 2026

Conditions
Breast Cancer
Interventions
DRUG

Endocrine Therapy and a CDK 4/6 inhibitor

Participants with untreated metastatic disease receiving ET and a CDK 4/6 i as first line therapy.

DRUG

Endocrine Therapy and a CDK 4/6 inhibitor

Participants initiating a CDK 4/6 i after progression on ET.

Trial Locations (1)

21287

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Biovica International AB
All Listed Sponsors
collaborator

Safeway Foundation

UNKNOWN

collaborator

Biovica International AB

UNKNOWN

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER